Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
NCT06041516Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADCT-701 in Neuroendocrine neoplasm (NEN), adrenocortical carcinoma (ACC) and malignant peripheral nerve sheath tumor (MPNST), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jun 2024; status: recruiting.
02
Drugs
ADCT-701
03
Conditions
Neuroendocrine neoplasm (NEN)adrenocortical carcinoma (ACC)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT06041516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041516.